Literature DB >> 14500637

Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens.

Julius A Potian1, Hana Aviv, Nicholas M Ponzio, Jonathan S Harrison, Pranela Rameshwar.   

Abstract

Trans-differentiation of stem cells shows promise for use in tissue repair medicine. Although poorly defined, mesenchymal stem cells (MSC) appear useful for applications in repair medicine. Despite the low frequency of MSC, they are relatively easy to expand. The expression of MHC class II on MSC, however, could deter their use in repair medicine, since these molecules could stimulate an allogeneic host response. This study sought to compare the immune stimulatory and suppressive effects of MSC. Primary human MSC were cultured from bone marrow aspirates and then passaged at least three times before use in assays. Morphologically, MSC were symmetrical; were SH2(+), MHC class II(+), CD45(-), CD44(+), CD31(-), CD14(-), proly-4-hydroxylase(-); and showed normal karyotype patterns and elevated telomerase activities. MSC elicited significant stimulatory responses when cocultured with allogeneic PBMC. Despite the production of different types of growth factors, allogeneic effects of MSC could not be explained by the production of these growth factors. One-way MLR reactions were significantly blunted by third-party MSC. Similar suppression was not observed for responses to three different recall Ags. Based on these functional differences by MSC in responses to allo- and recall Ags, we examined whether MSC could exert veto-like functions. We showed that MSC could blunt the cytotoxic effects of allogeneic-induced effectors to mitogen-activated targets. The results showed that although MSC elicited allogeneic responses in a model that mimics a graft-vs-host reaction, they also exerted veto-like activity, but caused no effect on responses to recall Ags.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500637     DOI: 10.4049/jimmunol.171.7.3426

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  115 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 2.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 3.  The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease.

Authors:  Brent R Weil; Mariuxi C Manukyan; Jeremy L Herrmann; Aaron M Abarbanell; Jeffrey A Poynter; Yue Wang; Daniel R Meldrum
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

4.  Allogeneic mesenchymal stem cells transplantation in patients with refractory RA.

Authors:  Jun Liang; Xia Li; Huayong Zhang; Dandan Wang; Xuebing Feng; Hong Wang; Bingzhu Hua; Bujun Liu; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2011-08-12       Impact factor: 2.980

5.  Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential.

Authors:  Sergey V Smirnov; Ryhor Harbacheuski; Anita Lewis-Antes; Hua Zhu; Pranela Rameshwar; Sergei V Kotenko
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

Review 6.  Immune response to stem cells and strategies to induce tolerance.

Authors:  Puspa Batten; Nadia A Rosenthal; Magdi H Yacoub
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

7.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.

Authors:  Jennifer L Chan; Katherine C Tang; Anoop P Patel; Larissa M Bonilla; Nicola Pierobon; Nicholas M Ponzio; Pranela Rameshwar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

8.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

Review 9.  Stem cell paracrine actions and tissue regeneration.

Authors:  Priya R Baraniak; Todd C McDevitt
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

Review 10.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.